• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marijuana Stock Movers For May 29, 2024

    5/29/24 4:30:05 PM ET
    $CRON
    $GENE
    $UGRO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRON alert in real time by email

    GAINERS:

    • Global Hemp Group (OTC:GBHPF) shares closed up 218.18% at $0.07
    • 1933 Industries (OTC:TGIFF) shares closed up 43.96% at $0.01
    • Rocky Mountain High (OTC:RMHB) shares closed up 14.41% at $0.01
    • Target Group (OTC:CBDY) shares closed up 14.29% at $0.00
    • Urban-gro (NASDAQ:UGRO) shares closed up 9.98% at $1.56
    • RIV Capital (OTC:CNPOF) shares closed up 7.29% at $0.09
    • Leafbuyer Techs (OTC:LBUY) shares closed up 3.54% at $0.02
    • CV Sciences (OTC:CVSI) shares closed up 3.45% at $0.06

    LOSERS:

    • The Flowr (OTC:FLWPF) shares closed down 50.00% at $0.0001
    • Heritage Cannabis Holding (OTC:HERTF) shares closed down 25.00% at $0.00
    • Affinor Growers (OTC:RSSFF) shares closed down 20.00% at $0.08
    • Genetic Technologies (NASDAQ:GENE) shares closed down 15.35% at $1.89
    • Pharmadrug (OTC:LMLLF) shares closed down 14.40% at $0.02
    • Auxly Cannabis Group (OTC:CBWTF) shares closed down 10.13% at $0.03
    • Nextleaf Solutions (OTC:OILFF) shares closed down 9.09% at $0.10
    • C21 Investments (OTC:CXXIF) shares closed down 8.36% at $0.30
    • EnWave (OTC:NWVCF) shares closed down 8.28% at $0.17
    • Global Compliance (OTC:FUAPF) shares closed down 7.41% at $0.01
    • CordovaCann (OTC:LVRLF) shares closed down 7.32% at $0.07
    • MariMed (OTC:MRMD) shares closed down 4.89% at $0.22
    • Cronos Group (NASDAQ:CRON) shares closed down 4.85% at $2.56
    • Kaya Holdings (OTC:KAYS) shares closed down 3.77% at $0.04
    • Indiva (OTC:NDVAF) shares closed down 3.69% at $0.04
    • Curaleaf Holdings (OTC:CURLF) shares closed down 3.61% at $4.50

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON
    $GENE
    $UGRO

    CompanyDatePrice TargetRatingAnalyst
    Cronos Group Inc.
    $CRON
    1/27/2026Buy
    Canaccord Genuity
    Cronos Group Inc.
    $CRON
    11/2/2022$3.00Mkt Perform
    Bernstein
    Cronos Group Inc.
    $CRON
    7/28/2022Hold → Buy
    Canaccord Genuity
    Cronos Group Inc.
    $CRON
    5/11/2022Neutral → Sector Outperform
    CIBC
    Cronos Group Inc.
    $CRON
    3/22/2022Underweight → Equal Weight
    Barclays
    urban-gro Inc.
    $UGRO
    3/21/2022$20.00Buy
    Maxim Group
    Cronos Group Inc.
    $CRON
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    Cronos Group Inc.
    $CRON
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    More analyst ratings

    $CRON
    $GENE
    $UGRO
    SEC Filings

    View All

    urban-gro Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - urban-gro, Inc. (0001706524) (Filer)

    2/5/26 7:01:05 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    SEC Form 10-Q filed by urban-gro Inc.

    10-Q - urban-gro, Inc. (0001706524) (Filer)

    2/3/26 5:29:49 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    urban-gro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - urban-gro, Inc. (0001706524) (Filer)

    1/30/26 5:19:02 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $CRON
    $GENE
    $UGRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Gorenstein Michael Ryan converted options into 166,642 shares and covered exercise/tax liability with 65,002 shares, increasing direct ownership by 0.81% to 12,610,412 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    12/16/25 5:14:47 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Weigensberg Arye converted options into 6,423 shares, increasing direct ownership by 5% to 135,892 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    12/16/25 5:12:39 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by SVP, Head of Cronos Israel Wagner Adam

    4 - Cronos Group Inc. (0001656472) (Issuer)

    11/10/25 5:08:04 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    $GENE
    $UGRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy

    TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON, TSX:CRON) ("Cronos" or the "Company"), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones®, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical mar

    2/2/26 2:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos to enter the Netherlands with acquisition of Europe's largest adult-use cannabis company

    Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2 Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe Enables borderless product strategy, leveraging investments in genetics, R&D, and product development TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, is pleased to announce that its wholly-owned subsidiary has entered into a definitive share sale and purchase agreeme

    12/9/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Launches Premium Lord Jones Live Resin Fusions™ in Canada

    TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced is expanding its portfolio for its Lord Jones® brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™ pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusions™ are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavo

    11/25/25 7:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    $GENE
    $UGRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    $GENE
    $UGRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wilks Lewis bought $29,000 worth of shares (20,000 units at $1.45), increasing direct ownership by 12% to 184,108 units (SEC Form 4)

    4 - urban-gro, Inc. (0001706524) (Issuer)

    6/6/24 5:23:34 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $CRON
    $GENE
    $UGRO
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    3/19/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

    MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

    9/11/24 8:15:00 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRON
    $GENE
    $UGRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by urban-gro Inc. (Amendment)

    SC 13G/A - urban-gro, Inc. (0001706524) (Subject)

    6/10/24 4:48:01 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by urban-gro Inc. (Amendment)

    SC 13G/A - urban-gro, Inc. (0001706524) (Subject)

    2/14/24 4:06:57 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $CRON
    $GENE
    $UGRO
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025

    TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    10/23/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025

    TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 second quarter earnings conference call on Thursday, August 7, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/25/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

    TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

    4/24/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    $GENE
    $UGRO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary